Latest Conference Articles
Advertisement
Advertisement
Trending on OncLive
1
Durvalumab Plus Enfortumab Vedotin Improves Survival in Cisplatin-Ineligible MIBC
2
Adjuvant Intismeran Autogene Plus Pembrolizumab Improves RFS and DMFS in Melanoma
3
Atirmociclib Plus Fulvestrant Improves PFS in HR+/HER2– Advanced Breast Cancer
4
DASL-HiCaP: Darolutamide Plus ADT and Radiation Therapy Improves MFS in Very High-Risk Localized Prostate Cancer
5